Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate Cenvacibart (REGN7508), a Monoclonal Antibody Against Factor XI, for Secondary Stroke Prevention (ROXI-DAISEN)

NCT07876492 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT07876492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07876492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate Cenvacibart (REGN7508), a Monoclonal Antibody Against Factor XI, for Secondary Stroke Prevention (ROXI-DAISEN)
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 20, 2026
Completion date
December 15, 2029
Enrollment
6,106 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

secondary stroke